Poster
# 110

Main Page

6th Internet World Congress for Biomedical Sciences

IndexIndex
One-page version
Dynamic pages

Augmentation of antidepressant therapy with 5-HT autoreceptor antagonists: receptor autoradiographic studies of pindolol

Trevor Sharp(1), Elena Castro(2)
(1)Department of Clinical Pharmacology. University of Oxford - Oxford. United Kingdom
(2) Clinical Pharmacology. University of Oxford - Oxford. United Kingdom

[ABSTRACT] [INTRODUCTION] [MATERIAL & METHODS] [RESULTS] [FIGURES] [DISCUSSION] [CONCLUSIONS] [ACKNOWLEDGEMENTS] [REFERENCES] [Discussion Board]
ACKNOWLEDGEMENTS Previous: GENTAMICIN CONTAINING SURGICAL BONE CEMENT: IN VITRO ELUTION CHARACTERISTICS OF PALACOS® AND PALAMED® Previous: Differential effects of 18-Methoxycoronaridine (18-MC) on the behavioural and neurochemical responses to chronic cocaine and morphine: Implications for sensitization in the mediation of drug addiction ABSTRACT
[Pharmacology]
Next: Effects Of Long Term Treatment With Amlodipine Or Nebivolol In SHRs. 		[Psychiatry]
Next: Central Neurochemical Alterations Induced by Acute and Repeated Systemic Interleukin-2 Administration

REFERENCES

  1. Auerbach S.B., Lundberg J.F., and Hjorth S. (1995) Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology 34, 89-96.
  2. Blier P., and De Montigny C. (1994) Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15, 220-226.
  3. Burnet P.W.J., Eastwood S.L., and Harrison P. (1997) [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 30, 565-574.
  4. Castro M.E., Pei Q., and Sharp T. (1999) Effect of an SSRI given in combination with a 5-HT1A antagonist on forebrain expression of the immediate early gene ARC. Br. J. Pharmacol., in press.
  5. Clifford E.M., Gartside S.E., Umbers V., Cowen P., Hajós M., and Sharp T. (1998) Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br. J. Pharmacol. 124, 206-212.
  6. Corradetti R., Laaris N., Hanoum N., Laporte A-M., Le Poul E., Hamon M., and Lanfuney L. (1998) Antagonist properties of (-) pindolol and WAY100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br. J. Pharmacol. 123, 449-462.
  7. Gartside S.E., Umbers V., Clifford E.M., and Sharp T. (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115, 1064-1070.
  8. Hajós M., Gartside S.E., and Sharp T. (1995) Inhibition of median and dorsal raphé neurones by the selective 5-HT reuptake inhibitor paroxetine. Naunyn-Schmiedeberg´s Arch. Pharmacol. 351, 624-629.
  9. Hoyer D., Engel G., and Kalman H.O. (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]8-OH-DPAT, [125I]iodocianopindolol, [3H]mesulergine and [3H]ketanserin. Eur. J. Pharmacol. 118, 13-23.
  10. Hirani E., Opacka-Juffry J., Gunn R., Khan I., Sharp T., and Hume S. (1999) Pindolol occupancy of 5-HT1A receptors measured in vivo using small animal positron emission tomography with carbon-11 labelled WAY-100635. Synapse, in press. Khawaja X. (1995) Quantitative autoradiography characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res. 673, 217-225.
  11. McAskill R., Mir S., and Taylor D. (1998) Pindolol augmentation of antidepressant therapy. Br. J. Pharmacol. 173, 203-208.
  12. Newman-Tancredi A., Chaput C., Gavaudan S., Verrièle L., and Millan M.J. (1998) Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. Neuropsychopharmacology 18, 395-398.
  13. Rabiner E.A., Gunn R.N., Castro M.E., Sargent P.A., Cowen P.J., Koepp M.L., Meyer J.H., Bench C.J., Harrison P.H., Pazos A., Sharp T., and Grasby P.M. (1999) ß-blocker binding to human 5-HT1A receptors in vitro and in vivo: implications for antidepressant therapy. Neuropsychopharmacology, in press. 14. Raurich A., Mengod G., Artigas F., and Cortés R. (1999) Displacement of the binding of 5-HT1A receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain. Synapse 34, 68-76. 15. Romero L., Bel N., Artigas F., de Montigny C., and Blier P. (1996) Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15, 349-360.

Discussion Board
Discussion Board

Any Comment to this presentation?

[ABSTRACT] [INTRODUCTION] [MATERIAL & METHODS] [RESULTS] [FIGURES] [DISCUSSION] [CONCLUSIONS] [ACKNOWLEDGEMENTS] [REFERENCES] [Discussion Board]
ACKNOWLEDGEMENTS Previous: GENTAMICIN CONTAINING SURGICAL BONE CEMENT: IN VITRO ELUTION CHARACTERISTICS OF PALACOS® AND PALAMED® Previous: Differential effects of 18-Methoxycoronaridine (18-MC) on the behavioural and neurochemical responses to chronic cocaine and morphine: Implications for sensitization in the mediation of drug addiction ABSTRACT
[Pharmacology]
Next: Effects Of Long Term Treatment With Amlodipine Or Nebivolol In SHRs. 		[Psychiatry]
Next: Central Neurochemical Alterations Induced by Acute and Repeated Systemic Interleukin-2 Administration
Trevor Sharp, Elena Castro
Copyright © 1999-2000. All rights reserved.
Last update: 26/01/00